Business
AVRICORE HEALTH CORPORATE UPDATE: Q1 Results and Ongoing Progress Report
VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year. For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068. Plan the Work – Work the Plan The C
About this update from Avricore Health Inc.
[{"type":"image","alt":"Avricore Health Inc.","displaySize":"","headline":null,"caption":"Avricore Health Inc.","className":"","disableSlideshowImg":false,"size":{"original":{"width":300,"height":101,"url":"https://media.zenfs.com/en/globenewswire.com/c0da71ca0c3b0e4707187cbddf04634c"},"resized":{"url":"https://s.yimg.com/ny/api/res/1.2/GN_4BMbCvGMoKNzC03ix.Q--/YXBwaWQ9aGlnaGxhbmRlcjt3PTQyMDtoPTE0MTtjZj13ZWJw/https://media.zenfs.com/en/globenewswire.com/c0da71ca0c3b0e4707187cbddf04634c","width":300,"height":101}},"lazy":false},{"type":"text","content":"VANCOUVER, British Columbia, June 02, 2025 (GLOBE NEWSWIRE) -- AVRICORE HEALTH INC. (TSXV: AVCR) (the “Company” or “Avricore”) reports on its result for the first quarter of 2025 and its progress towards expansion objectives for the balance of the year.","length":258,"tagName":"p"},{"type":"text","content":"For the three months ended March 31, 2025 the Company realized revenues of $434,061 with a gross profit of $346,297. The Company recorded a comprehensive loss of $77,300 with a net increase in cash of $137,068.","length":210,"tagName":"p"},{"type":"text","content":"Plan the Work – Work the Plan","length":29,"tagName":"p"},{"type":"text","content":"The Company is currently executing its plan to significantly expand HealthTab, its wholly owned turnkey point-of-care testing (POCT) platform that empowers pharmacies to become proactive community diagnostic centers, in the United Kingdom — a decision aligned with the region’s robust healthcare market and significant investment in pharmacy-led services.","length":355,"tagName":"p"},{"type":"text","content":"To realize its goals, the Company has ensured its cash position is strong and has the assets needed to capitalize on scale up demand. Therefore, while its previously announced scale down of revenues within Canada has taken effect, the Company continues to be very well positioned to realize its objectives.","length":306,"tagName":"p"},{"type":"text","content":"“Every day, we’re proving just how valuable HealthTab™ can be in the hands of pharmacists,” said Hector Bremner, CEO of Avricore Health. “The NHS is paving the way for expanded pharmacy services, and our work in the London feasibility study gives us real confidence that HealthTab™ will be part of that future.”","length":311,"tagName":"p"},{"type":"text","content":"Tackling the Need","length":17,"ta...